ESC Updates Guidelines for Ventricular Arrhythmia, Sudden Death ESC Updates Guidelines for Ventricular Arrhythmia, Sudden Death
ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death have undergone an important overhaul since the 2015 edition.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 16, 2022 Category: Cardiology Tags: Cardiology News Source Type: news

Total Alcohol Intake Not Linked to Ventricular Arrhythmia Risk
TUESDAY, Dec. 28, 2021 -- Total alcohol consumption is not associated with an increased risk for incident ventricular arrhythmia (VA), while there is a U-shaped association for alcohol consumption with the risk for sudden cardiac death (SCD),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 28, 2021 Category: Pharmaceuticals Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Provides Update on Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Plus Prednisone Combination
RARITAN, N.J., April 19, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that regulatory submissions based on the Phase 3 ACIS study, which evaluated the combination of ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC), will not be pursued. As presented at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium in February 2021, the ACIS study met its primary endpoint of radiographic progression-free survival (rPFS); however, combination...
Source: Johnson and Johnson - April 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA® and ZYTIGA® plus prednisone (combination arm) or placebo and ZYTIGA® pl...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said Craig Tendler, M...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

U.S. FDA Approves New Pediatric Formulation of SIRTURO ® (bedaquiline) as Part of Combination Therapy to Treat Children with Pulmonary Multidrug-Resistant Tuberculosis
NEW BRUNSWICK, NJ, May 27, 2020 — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new pediatric formulation of SIRTURO® (bedaquiline). SIRTURO® is now indicated for use as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multidrug-resistant tuberculosis (MDR‑TB). In the U.S., the medicine should be reserved for use when an effective treatment regimen cannot otherwise be provided. This indication received accelerated appro...
Source: Johnson and Johnson - May 27, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Inherited arrhythmia in young Finnish Leonbergers under investigation
(University of Helsinki) Inherited malignant ventricular arrhythmia is a fairly common disorder among Finnish Leonbergers under three years of age, with the most severe cases potentially resulting in sudden death. Researchers are striving to identify the gene mutation underlying the disorder. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 10, 2020 Category: Biology Source Type: news

ANI Pharmaceuticals Announces Launch of Bretylium Tosylate Injection, USP 50 mg/mL
BAUDETTE, Minn., Dec. 18, 2019 -- (Healthcare Sales & Marketing Network) -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Bretylium Tosylate Injection USP, 50 mg/mL. Bretylium Tosylate is a class III antiarrhyth... Biopharmaceuticals, Cardiology, Product Launch ANI Pharmaceuticals, Bretylium, ventricular arrhythmia, tachycardia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 18, 2019 Category: Pharmaceuticals Source Type: news

Hypoglycemic episodes increase risk of cardiac arrest
Hypoglycemic episodes in patients with type 2 diabetes increase risk of sudden cardiac arrest and ventricular arrhythmia, according to a study published inDiabetes/Metabolism Research and Reviews.Speciality Medical Dialogues (Source: Society for Endocrinology)
Source: Society for Endocrinology - November 11, 2019 Category: Endocrinology Source Type: news

Hypoglycemia Increases Risk for Sudden Cardiac Arrest in T2DM
WEDNESDAY, Oct. 30, 2019 -- Hypoglycemic episodes may increase the risk for ventricular arrhythmia (VA) and sudden cardiac arrest (SCA) among patients with type 2 diabetes, according to a study published online Oct. 26 in Diabetes/Metabolism... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 30, 2019 Category: Pharmaceuticals Source Type: news

Fitness Linked to Lower Ventricular Arrhythmia Risk Later Fitness Linked to Lower Ventricular Arrhythmia Risk Later
The finding fits with abundant evidence that cardiorespiratory fitness, here measured during exercise tests in men followed for decades, protects against cardiovascular events long-term.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 26, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

ENCORE-VT: Noninvasive Ablation of VT Could Disrupt EP ENCORE-VT: Noninvasive Ablation of VT Could Disrupt EP
A small study suggests that ventricular arrhythmia may be treated without the need for catheters and anesthesia. John Mandrola, MD, is impressed with the findings and the investigators ' lack of hyperbole.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 13, 2018 Category: Consumer Health News Tags: Cardiology Expert Column Source Type: news

Chest Pain Drug Ranolazine Falls Short in Preventing First Episode of Ventricular Arrhythmia or Death
A trial of more than 1,000 patients with implantable cardioverter defibrillators found that the chest pain drug ranolazine was safe but didn ’t decrease the likelihood of the first occurrence of ventricular arrhythmias or death in this high-risk population. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - September 5, 2018 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news

Chest pain drug falls short in preventing first episode of ventricular arrhythmia or death
(University of Rochester Medical Center) A trial of more than 1,000 patients with implantable cardioverter defibrillators found that the drug ranolazine (used to treat chest pain; brand name Ranexa ® ) was safe but didn't decrease the likelihood of the first occurrence of ventricular arrhythmias or death in this high-risk population. The drug did lower the risk for recurrent ventricular tachycardia by 30 percent, suggesting it could be a treatment option for this very sick population for which there are limited therapies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 28, 2018 Category: International Medicine & Public Health Source Type: news